MET: a critical player in tumorigenesis and therapeutic target - Test2 - elhamkhani - TriplyDB

MET: a critical player in tumorigenesis and therapeutic target

MET: a critical player in tumorigenesis and therapeutic target

http://www.wikidata.org/entity/Q27008925

about

Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility Complete or partial reduction of the Met receptor tyrosine kinase in distinct circuits differentially impacts mouse behavior Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets Receptor tyrosine kinase signaling: regulating neural crest development one phosphate at a time Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells.The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth Hepatocyte growth factor ameliorates hyperglycemia and corrects β-cell mass in IRS2-deficient mice The MET gene is a common integration target in avian leukosis virus subgroup J-induced chicken hemangiomas.Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.Targeted therapy in gastroesophageal cancers: past, present and future.Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells.MET in gastric cancer--discarding a 10% cutoff rule Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Cellular processes associated with LRRK2 function and dysfunction MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches.YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma.miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.Development of antibody-based c-Met inhibitors for targeted cancer therapy.In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model.Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer.Management of Atypical Renal Cell Carcinomas.High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma.The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

P2860

Q21132280-9AE93EFC-1782-4D19-925A-5631AFF703CF Q27308835-D2F5DE89-8FC3-4ABC-9731-C151A6F0015A Q27320671-68CAD242-EC7A-4167-A40F-9A5617FC0145 Q28081193-DC677FD4-9430-49D9-9430-780B3E626004 Q28083779-644C687A-B4C5-40D3-ADD2-4DC80A5CC8CC Q34141440-4819D431-E56D-405B-9790-9824A12B7824 Q34158454-E299E544-50C2-4BC6-8542-2B3FE5A94197 Q34287371-16E75426-FA3C-43A8-8A3D-4427A5FE8BEE Q34334418-19D5AF1F-CFAB-42C5-BA62-3E04F09180F1 Q34603094-23FAB49E-8E11-4D09-966B-FCCFBF56F8B5 Q35488562-7DD6FA14-1563-4A19-8AA4-AF416FE4A92A Q35545814-1E613034-CD29-42C0-B9AA-E6C52B010B44 Q36214648-530996B6-A433-46D0-9D76-ABE54DC54ACD Q36294579-F4119AEC-433A-46B0-AC9F-CC021248A7BD Q36524826-33036ECE-8C3E-4E70-B997-1C5957E947C1 Q36554574-0AFBB0BA-D37F-4927-BFB4-5AA805ADAA80 Q37293109-7763519A-D67C-46DA-B0C8-3EEFA3F9808A Q37628915-E5631F46-9ED7-4B3B-A4E1-233948994904 Q37672483-D92E0304-27A6-4EEF-A2E0-2FCE1F94EDEA Q38236096-C9EB335C-B628-49BC-891E-7867A60A3247 Q38433725-459CB745-E068-4249-AD88-CE82392FCDA2 Q38476204-1B9005EB-E304-4AD9-A660-969923DB2604 Q38498207-1B4A46F9-8994-4DAC-8474-332561F9F86C Q38674137-396452CC-181C-4FAA-BFAE-8583D75E7A92 Q38720873-7DE779A2-38B7-4A8A-AAED-3834896C2FE0 Q38845681-2FF6FDDE-DBBF-4EB9-8248-8A611D021601 Q38880117-E3D5B345-C458-464B-A134-84A1D413EB68 Q38912279-1759D59C-7E11-48C2-AD08-397F9A0C5D1B Q41158794-97974406-C7FC-4408-97A5-EB7BA45EC617 Q41258130-C55A07CB-18F8-4840-9E89-7F2CEBC4BED6 Q41825773-910952B2-4F28-45D8-A8FD-4476D1FB6870 Q45991749-9B5E6033-715F-40F5-91C2-A68E2859B195 Q46668930-AA6D5FB4-F519-4092-944A-C3EA6E5F39AA Q47947817-4966C433-F4DB-46CF-A8AA-D6EF53B11A33 Q49386899-899F8AF2-6983-4520-9D3B-7C14BD67E80B Q50156185-59D0559C-5992-4D28-8C68-225FEAC45A8D Q51689102-E06B77E1-1D3A-48F3-95E2-481BD723C339 Q51795590-EA796D11-1A9E-4541-BEBC-B8D2F77CF98E Q55085143-ECD259D6-AA5D-42D7-BA69-0515DF041EA0 Q57162835-81154461-7609-4A3E-8172-904D5C8BD5F7

P2860

MET: a critical player in tumorigenesis and therapeutic target

http://www.wikidata.org/entity/Q27008925

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

MET: a critical player in tumorigenesis and therapeutic target

@ast

MET: a critical player in tumorigenesis and therapeutic target

@en

MET: a critical player in tumorigenesis and therapeutic target

@nl

type

label

MET: a critical player in tumorigenesis and therapeutic target

@ast

MET: a critical player in tumorigenesis and therapeutic target

@en

MET: a critical player in tumorigenesis and therapeutic target

@nl

prefLabel

MET: a critical player in tumorigenesis and therapeutic target

@ast

MET: a critical player in tumorigenesis and therapeutic target

@en

MET: a critical player in tumorigenesis and therapeutic target

@nl

P1433

Q27008925-FD062A35-2FA7-4F90-88F0-4CD5FFE781C0

P1476

Q27008925-DC92C21C-4A10-4585-8A0A-7E5A7BF5AB3A

P2093

Q27008925-3EB6A994-733A-44ED-954C-D5AEB192601E

Q27008925-9E750BA8-35A7-455F-93FB-6296F77D1D7F

Q27008925-B57C9140-104B-48DD-A8C0-98DFA2692B84

P2860

Q27008925-0504486D-3425-440E-8044-AF0E3E255469

Q27008925-0A4ECBA8-DB3C-43D6-9ECD-594F5E59FB87

Q27008925-120453B0-8F7B-41EC-A89E-D45745DD1D78

Q27008925-12A84152-43AA-4A28-BFD6-C5A3EA6BEB9A

Q27008925-177FC24A-06B6-4E3B-8336-F71B8E998300

Q27008925-1847E737-3A27-4A69-BF2C-C682AFF7F619

Q27008925-199F7AAD-0E9E-4BCC-ABC8-334F2DD55692

Q27008925-19BED7AA-CD8A-43C7-9CE7-E0D89BCB4CEA

Q27008925-1A177381-573E-41AF-91FE-E0990A7BBDD1

Q27008925-1AB5076B-5714-4106-ABC9-EF7237C52698

P31

Q27008925-8AABD5B5-354E-4FE8-8563-7C4399C2CFE9

P3181

Q27008925-F334FE62-8A6B-457F-ADB5-A632327D7603

P356

Q27008925-F3F5A2A3-FF77-44F0-B119-4EAB99676582

P407

Q27008925-D381FF47-F16F-48F1-8AE7-EFBA0D0CD40B

P433

Q27008925-2A7C3BE3-77C1-43BF-9363-B8A60DE2A8F0

P478

Q27008925-A7F1C2F9-B9EB-4B1A-B908-B54750A6249A

P577

Q27008925-CBB47E91-8F10-4C0D-A89C-460D625EF987

P5875

Q27008925-BC7CD2A2-AD6A-4853-9987-016E73B01631

P698

Q27008925-FCCCBA3A-2DF1-4A2E-B2C3-55C1D9DB3561

P932

Q27008925-3C7E2182-F318-4B2C-A6A5-CBDDEB766FCD

P3181

P356

CSHPERSPECT.A009209

P1433

Cold Spring Harbor Perspectives in Biology

P1476

MET: a critical player in tumorigenesis and therapeutic target

@en

P2093

C. R. Graveel

http://www.w3.org/2001/XMLSchema#string

D. Tolbert

http://www.w3.org/2001/XMLSchema#string

G. F. Vande Woude

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Molecular cloning and expression of human hepatocyte growth factor

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Activation of the zymogen of hepatocyte growth factor activator by thrombin

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

Essential role of Gab1 for signaling by the c-Met receptor in vivo

P31

scholarly article

P3181

4394057

http://www.w3.org/2001/XMLSchema#string

P356

10.1101/CSHPERSPECT.A009209

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244482411

http://www.w3.org/2001/XMLSchema#string

P698

23818496

http://www.w3.org/2001/XMLSchema#string

P932

3685898

http://www.w3.org/2001/XMLSchema#string